<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OFLOXACIN- ofloxacin solution/ drops </strong><br>Hi-Tech Pharmacal Co., Inc.<br></p></div>
<h1>Ofloxacin Ophthalmic Solution, 0.3%<br>Sterile</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_e18f57cc-fc78-42b0-bb5c-fe1e1ac905b8"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Ofloxacin ophthalmic solution 0.3% is a sterile ophthalmic solution. It is a fluorinated carboxyquinolone anti-infective for topical ophthalmic use.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0039dd20-1607-4e10-a29f-2a87ccca8fb3"></a><a name="section-1.1"></a><p></p>
<h2>Chemical Name:</h2>
<p class="First">(±)-9-Fluoro-2, 3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4 benzoxazine-6-carboxylic acid</p>
<p><img alt="Ofloxacin Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7882f70e-d228-4c52-9390-0d927c51af1f&amp;name=0095d1d6-d83e-4e22-aa61-3b4753f0753b-01.jpg"></p>
<p><span class="Bold">Contains:</span></p>
<p><span class="Bold">A</span><span class="Bold">ctive: </span>ofloxacin 0.3% (3 mg/mL). </p>
<p><span class="Bold">Preservative: </span>benzalkonium chloride (0.005%). </p>
<p><span class="Bold">Inactives: </span>sodium chloride and purified water. May also contain hydrochloric acid and/or sodium hydroxide to adjust pH. </p>
<p>Ofloxacin ophthalmic solution is unbuffered and formulated with a pH of 6.4 (range - 6.0 to 6.8). It has an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of 300 mOsm/kg. Ofloxacin is a fluorinated 4-quinolone which differs from other fluorinated 4-quinolones in that there is a six member (pyridobenzoxazine) ring from positions 1 to 8 of the basic ring structure. </p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_3eff663d-2036-4111-ab5f-67137eafcae9"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_08b5efad-b2f9-4375-bbf4-9c31ba0acf15"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics: </h2>
<p class="First">Serum, urine and tear concentrations of ofloxacin were measured in 30 healthy women at various time points during a ten-day course of treatment with ofloxacin ophthalmic solution. The mean serum ofloxacin concentration ranged from 0.4 ng/mL to 1.9 ng/mL. Maximum ofloxacin concentration increased from 1.1 ng/mL on day one to 1.9 ng/mL on day 11 after QID dosing for 10 1/2 days. Maximum serum ofloxacin concentrations after ten days of topical ophthalmic dosing were more than 1000 times lower than those reported after standard oral doses of ofloxacin. </p>
<p>Tear ofloxacin concentrations ranged from 5.7 to 31 µg/g during the 40 minute period following the last dose on day 11. Mean tear concentration measured four hours after topical ophthalmic dosing was 9.2 µg/g. </p>
<p>Corneal tissue concentrations of 4.4 µg/mL were observed four hours after beginning topical ocular application of two drops of ofloxacin ophthalmic solution every 30 minutes. Ofloxacin was excreted in the urine primarily unmodified.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_730a7364-96f3-43e1-bdb1-64f3e2e8365c"></a><a name="section-2.2"></a><p></p>
<h2>Microbiology: </h2>
<p class="First">Ofloxacin has in vitro activity against a broad range of gram-positive and gram-negative aerobic and anaerobic bacteria. Ofloxacin is bactericidal at concentrations equal to or slightly greater than inhibitory concentrations. Ofloxacin is thought to exert a bactericidal effect on susceptible bacterial cells by inhibiting DNA gyrase, an essential bacterial enzyme which is a critical catalyst in the duplication, transcription, and repair of bacterial DNA. </p>
<p>Cross-resistance has been observed between ofloxacin and other fluoroquinolones. There is generally no cross-resistance between ofloxacin and other classes of antibacterial agents such as beta-lactams or aminoglycosides. </p>
<p>Ofloxacin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms both in vitro and clinically, in conjunctival and/or <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulcer</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold"><a href="#i4i_indications_id_8203dc83-74e3-4d25-8460-e5a456882093">INDICATIONS AND USAGE</a></span> section. </p>
<a name="id_34ad2a71-62ab-4984-b2cc-be65a45ec684"></a><table width="431.000">
<col width="49.7%">
<col width="50.3%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top"><span class="Bold">AEROBES, GRAM-POSITIVE:</span></td>
<td align="left" valign="top"><span class="Bold">AEROBES, GRAM-NEGATIVE:</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Staphylococcus aureus</span></td>
<td align="left" valign="top"><span class="Italics">Enterobacter cloacae</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Staphylococcus epidermidis</span></td>
<td align="left" valign="top"><span class="Italics">Haemophilus influenzae</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Streptococcus pneumoniae</span></td>
<td align="left" valign="top"><span class="Italics">Proteus mirabilis</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">ANAEROBIC SPECIES:</span></td>
<td align="left" valign="top"><span class="Italics">Pseudomonas aeruginosa</span></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"><span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span></td>
<td class="Botrule" align="left" valign="top"><span class="Italics">Serratia marcescens*</span></td>
</tr>
</tbody>
</table>
<p>*Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></p>
<p>The safety and effectiveness of ofloxacin ophthalmic solution in treating ophthalmologic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to the following organisms have not been established in adequate and well-controlled clinical trials. Ofloxacin ophthalmic solution has been shown to be active in vitro against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of these organisms but the clinical significance in ophthalmologic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> is unknown.</p>
<a name="id_75374d9f-4234-443d-9541-11c76d884020"></a><table width="0.000">
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top"><span class="Bold">AEROBES, GRAM-POSITIVE:</span></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Enterococcus faecalis</span></td>
<td align="left" valign="top"><span class="Italics">Staphylococcus hominus</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Listeria monocytogenes</span></td>
<td align="left" valign="top"><span class="Italics">Staphylococcus simulans</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Staphylococcus capitis</span></td>
<td align="left" valign="top"><span class="Italics">Streptococcus pyogenes</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">AEROBES, GRAM-NEGATIVE:</span></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Acinetobacter calcoaceticus var. anitratus</span></td>
<td align="left" valign="top"><span class="Italics">Klebsiella pneumoniae</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Acinetobacter calcoaceticus var. Iwoffii</span></td>
<td align="left" valign="top"><span class="Italics">Moraxella (Branhamella) catarrhalis</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Citrobacter diversus</span></td>
<td align="left" valign="top"><span class="Italics">Moraxella lacunata</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Citrobacter freundii</span></td>
<td align="left" valign="top"><span class="Italics">Morganella morganii</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Enterobacter aerogenes</span></td>
<td align="left" valign="top"><span class="Italics">Neisseria gonorrhoeae</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Enterobacter agglomerans</span></td>
<td align="left" valign="top"><span class="Italics">Pseudomonas acidovorans</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Escherichia coli</span></td>
<td align="left" valign="top"><span class="Italics">Pseudomonas fluorescens</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Haemophilus parainfluenzae</span></td>
<td align="left" valign="top"><span class="Italics">Shigella sonnei</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Klebsiella oxytoca</span></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">OTHER:</span></td>
<td align="left" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"><span class="Italics">Chlamydia trachomatis</span></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_58951850-1efc-43e1-96e6-fb38bcca8e7e"></a><a name="section-2.3"></a><p></p>
<h2>Clinical Studies: </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e587a2bd-74fe-4002-b322-750ce7ebd042"></a><a name="section-2.3.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>: </h3>
<p class="First">In a randomized, double-masked, multicenter clinical trial, ofloxacin ophthalmic solution was superior to its vehicle after 2 days of treatment in patients with <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and positive conjunctival cultures. Clinical outcomes for the trial demonstrated a clinical improvement rate of 86% (54/63) for the ofloxacin treated group versus 72% (48/67) for the placebo treated group after 2 days of therapy. Microbiological outcomes for the same clinical trial demonstrated an eradication rate for causative pathogens of 65% (41/63) for the ofloxacin treated group versus 25% (17/67) for the vehicle treated group after 2 days of therapy. Please note that microbiologic eradication does not always correlate with clinical outcome in anti-infective trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_23e42431-0ad5-4ad0-bbb5-39a95616ad4b"></a><a name="section-2.3.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">Corneal Ulcers</span>:</h3>
<p class="First">In a randomized, double-masked, multi-center clinical trial of 140 subjects with positive cultures, ofloxacin ophthalmic solution treated subjects had an overall clinical success rate (complete re-epithelialization and no progression of the infiltrate for two consecutive visits) of 82% (61/74) compared to 80% (53/66) for the fortified antibiotic group, consisting of 1.5% tobramycin and 10% cefazolin solutions. The median time to clinical success was 11 days for the ofloxacin treated group and 10 days for the fortified treatment group.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_8203dc83-74e3-4d25-8460-e5a456882093"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Ofloxacin ophthalmic solution is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following bacteria in the conditions listed below: </p>
<a name="id_23a87789-7dca-48f2-b573-5784bbf1eb40"></a><table width="0.000">
<col>
<col>
<tbody class="Headless">
<tr class="First Toprule"><td align="left" colspan="2" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">CONJUNCTIVITIS</span>:</span></td></tr>
<tr>
<td align="left" valign="top"><span class="Bold">Gram-positive bacteria:</span></td>
<td align="left" valign="top"><span class="Bold"> Gram-negative bacteria: </span></td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="Italics">Staphylococcus aureus</span></p>
<p><span class="Italics">Staphylococcus epidermidis</span></p>
<span class="Italics">Streptococcus pneumoniae</span>
</td>
<td align="left" valign="top">
<p class="First"><span class="Italics">Enterobacter cloacae</span></p>
<p><span class="Italics">Haemophilus influenzae</span></p>
<p><span class="Italics">Proteus mirabilis</span></p>
<p><span class="Italics">Pseudomonas aeruginosa</span></p>
</td>
</tr>
<tr><td align="left" colspan="2" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">CORNEAL ULCERS</span>:</span></td></tr>
<tr>
<td align="left" valign="top"><span class="Bold">Gram-positive bacteria:</span></td>
<td align="left" valign="top"><span class="Bold">Gram-negative bacteria:</span></td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="Italics">Staphylococcus aureus</span></p>
<p><span class="Italics">Staphylococcus epidermidis</span></p>
<p><span class="Italics">Streptococcus pneumoniae </span></p>
</td>
<td align="left" valign="top">
<p class="First"><span class="Italics">Pseudomonas aeruginosa</span></p>
<p><span class="Italics">Serratia marcescens*</span></p>
</td>
</tr>
<tr><td align="left" colspan="2" valign="top"><span class="Bold">Anaerobic species:</span></td></tr>
<tr class="Botrule Last"><td align="left" colspan="2" valign="top"><span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span></td></tr>
</tbody>
</table>
<p>*Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_1c8d0bb3-f696-44ff-8f76-fca8aea3c624"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Ofloxacin ophthalmic solution is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ofloxacin, to other quinolones, or to any of the components in this medication. </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_29563d81-c86a-40c8-a493-a3f31f3cb0c0"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">NOT FOR INJECTION.</span></p>
<p>Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.</p>
<p>Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones, including ofloxacin. Some reactions were accompanied by <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (including laryngeal, pharyngeal or facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>), airway obstruction, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>. A rare occurrence of <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, which progressed to <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, has been reported in a patient who was receiving topical ophthalmic ofloxacin. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to ofloxacin occurs, discontinue the drug. Serious acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may require immediate emergency treatment. Oxygen and airway management, including intubation should be administered as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_1bd0ad4a-0400-470d-9001-28d029f34a4b"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_367d541b-d08d-41a1-a24e-98a3f4fa6485"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">As with other anti-infectives, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. Ofloxacin should be discontinued at the first appearance of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>.</p>
<p>The systemic administration of quinolones, including ofloxacin, has led to lesions or erosions of the cartilage in weight-bearing joints and other signs of <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals of various species. Ofloxacin, administered systemically at 10 mg/kg/day in young dogs (equivalent to 110 times the maximum recommended daily adult ophthalmic dose) has been associated with these types of effects. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_5c5a605e-c53f-484c-8429-06a722437a36"></a><a name="section-6.2"></a><p></p>
<h2>Information for patients</h2>
<p class="First">Avoid contaminating the applicator tip with material from the eye, fingers or other source. </p>
<p>Systemic quinolones, including ofloxacin, have been associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, even following a single dose. Discontinue use immediately and contact your physician at the first sign of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_6b3ae424-1972-4689-8dda-7857fbf15a51"></a><a name="section-6.3"></a><p></p>
<h2>Drug interactions</h2>
<p class="First">Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly. </p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_88c8d1ba-3132-48a3-be67-1d2fb1753950"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First">Long term studies to determine the carcinogenic potential of ofloxacin have not been conducted.</p>
<p>Ofloxacin was not mutagenic in the Ames test, in vitro and in vivo cytogenic assay, sister chromatid exchange assay (Chinese hamster and human cell lines), unscheduled DNA synthesis (UDS) assay using human fibroblasts, the dominant lethal assay, or mouse micronucleus assay. Ofloxacin was positive in the UDS test using rat hepatocyte, and in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay.</p>
<p>In fertility studies in rats, ofloxacin did not affect male or female fertility or morphological or reproductive performance at oral dosing up to 360 mg/kg/day (equivalent to 4000 times the maximum recommended daily ophthalmic dose). </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_570889ec-6a52-4f35-9965-3407c86685bd"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_e64ab2ad-a001-4860-9634-aa25605f6a67"></a><a name="section-6.5.1"></a><p></p>
<h3>Teratogenic effects</h3>
<p class="First"><span class="Bold">Pregnancy Category C:</span> Ofloxacin has been shown to have an embryocidal effect in rats and in rabbits when given in doses of 810 mg/kg/day (equivalent to 9000 times the maximum recommended daily ophthalmic dose) and 160 mg/kg/day (equivalent to 1800 times the maximum recommended daily ophthalmic dose). These dosages resulted in decreased fetal body weight and increased fetal mortality in rats and rabbits, respectively. Minor fetal skeletal variations were reported in rats receiving doses of 810 mg/kg/day. Ofloxacin has not been shown to be teratogenic at doses as high as 810 mg/kg/day and 160 mg/kg/day when administered to pregnant rats and rabbits, respectively. </p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_92ceb233-3b36-43a1-9afa-9d0d8556bf11"></a><a name="section-6.5.2"></a><p></p>
<h3>Nonteratogenic effects</h3>
<p class="First">Additional studies in rats with doses up to 360 mg/kg/day during late gestation showed no adverse effect on late fetal development, labor, delivery, lactation, neonatal viability, or growth of the newborn. </p>
<p>There are, however, no adequate and well-controlled studies in pregnant women. Ofloxacin ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_6ccb25d1-2e3f-43cf-a36d-e6d4cd48d075"></a><a name="section-6.6"></a><p></p>
<h2>Nursing mothers</h2>
<p class="First">In nursing women a single 200 mg oral dose resulted in concentrations of ofloxacin in milk which were similar to those found in plasma. It is not known whether ofloxacin is excreted in human milk following topical ophthalmic administration. Because of the potential for serious adverse reactions from ofloxacin in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_f9117c2b-48a4-4ff7-83bb-fe7c04c220ca"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric use</h2>
<p class="First">Safety and effectiveness in infants below the age of one year have not been established.</p>
<p>Quinolones, including ofloxacin, have been shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals after oral administration; however, topical ocular administration of ofloxacin to immature animals has not shown any <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span>. There is no evidence that the ophthalmic dosage form of ofloxacin has any effect on weight bearing joints. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_263309e2-c12b-4403-a91f-97478f6886d7"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_7dc971f9-e320-40e4-96a7-3b2ce55183d6"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">To report SUSPECTED ADVERSE REACTIONS, contact Hi-Tech Pharmacal Co., Inc. at 1-800-262-9010 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_de5271be-e441-4f8f-9acb-8e98cf703021"></a><a name="section-7.1"></a><p></p>
<h2>Ophthalmic Use: </h2>
<p class="First">The most frequently reported drug-related adverse reaction was transient ocular burning or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>. Other reported reactions include <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4167859" conceptname="Chemical keratitis">chemical conjunctivitis</span>/<span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, ocular/periocular/facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, foreign body sensation, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, tearing, dryness, and <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>. Rare reports of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> have been received. </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_5e765aa6-64d2-4c0a-8ae5-b18e64f27634"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dosage regimen for the treatment of <span class="Bold">bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span></span> is:</p>
<a name="id_b04c3d6d-3525-4959-b2e2-2f2747043523"></a><table width="432.000">
<col width="50.0%">
<col width="50.0%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top">Days 1 and 2</td>
<td align="left" valign="top">Instill one to two drops every two to four hours in the affected eye(s).</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Days 3 through 7</td>
<td class="Botrule" align="left" valign="top">Instill one to two drops four times daily.</td>
</tr>
</tbody>
</table>
<p>The recommended dosage regimen for the treatment of <span class="Bold">b</span><span class="Bold">acterial <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulcer</span></span> is:</p>
<a name="id_efb1deda-fb39-40e5-addf-6e6be94b7429"></a><table width="0.000">
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top">Days 1 and 2</td>
<td align="left" valign="top">Instill one to two drops into the affected eye every 30 minutes, while awake. Awaken at approximately four and six hours after retiring and instill one to two drops.</td>
</tr>
<tr>
<td align="left" valign="top">Days 3 through 7 to 9</td>
<td align="left" valign="top">Instill one to two drops hourly, while awake.</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Days 7 to 9 through treatment completion </td>
<td class="Botrule" align="left" valign="top">Instill one to two drops, four times daily.</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_9b54732f-0c87-40af-a8de-1fe277dd68ba"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Ofloxacin ophthalmic solution 0.3% is supplied sterile in opaque white LDPE plastic bottles and white dropper tips with beige high impact polystyrene (HIPS) caps as follows: </p>
<p>5 mL - NDC 50383-024-05</p>
<p>10 mL - NDC 50383-024-10</p>
<p>Note: Store at 20-25°C (68 - 77°F) [see USP Controlled Room Temperature].</p>
<p><br></p>
<p>Manufactured by:</p>
<p>Hi-Tech Pharmacal Co., Inc.</p>
<p>Amityville, NY 11701</p>
<p>Rev. 12/08 MG #24681</p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_c2708e23-6bfc-4274-b34c-14a23067f41c"></a><a name="section-10"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><img alt="Image of Carton - 10 mL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7882f70e-d228-4c52-9390-0d927c51af1f&amp;name=0095d1d6-d83e-4e22-aa61-3b4753f0753b-02.jpg"></p>
<p>NDC 50383-024-10</p>
<p><span class="Bold">Ofloxacin Ophthalmic Solution 0.3%</span></p>
<p><span class="Bold">Sterile</span></p>
<p><span class="Bold">10 mL</span></p>
<p><span class="Bold">Rx only</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OFLOXACIN 		
					</strong><br><span class="contentTableReg">ofloxacin solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50383-024</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OFLOXACIN</strong> (OFLOXACIN) </td>
<td class="formItem">OFLOXACIN</td>
<td class="formItem">3 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50383-024-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50383-024-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076615</td>
<td class="formItem">05/14/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Hi-Tech Pharmacal Co., Inc.
							(101196749)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0095d1d6-d83e-4e22-aa61-3b4753f0753b</div>
<div>Set id: 7882f70e-d228-4c52-9390-0d927c51af1f</div>
<div>Version: 2</div>
<div>Effective Time: 20120906</div>
</div>
</div> <div class="DistributorName">Hi-Tech Pharmacal Co., Inc.</div></p>
</body></html>
